FDMT Logo

4D Molecular Therapeutics, Inc. (FDMT) 

NASDAQ
Market Cap
$370.71M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
531 of 774
Rank in Industry
285 of 432

Largest Insider Buys in Sector

FDMT Stock Price History Chart

FDMT Stock Performance

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which …

Insider Activity of 4D Molecular Therapeutics, Inc.

Over the last 12 months, insiders at 4D Molecular Therapeutics, Inc. have bought $0 and sold $16.91M worth of 4D Molecular Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at 4D Molecular Therapeutics, Inc. have bought $44.27M and sold $7.83M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 850,000 shares for transaction amount of $13.6M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑05‑09.

List of Insider Buy and Sell Transactions, 4D Molecular Therapeutics, Inc.

2024-09-16SaleChief Legal Officer
500
0.001%
$16.33$8,165-46.42%
2024-08-19SaleChief Legal Officer
500
0.001%
$15.00$7,500-29.71%
2024-07-16SaleChief Legal Officer
1,750
0.0044%
$27.11$47,443-45.91%
2024-07-11SaleChief Legal Officer
1,996
0.0046%
$25.00$49,9000.00%
2024-07-10SaleChief Executive Officer
12,923
0.0268%
$22.49$290,5980.00%
2024-07-01SaleChief Legal Officer
4,248
0.0084%
$21.36$90,7580.00%
2024-06-24SaleChief Executive Officer
12,930
0.0248%
$23.10$298,711-36.73%
2024-06-17SaleChief Legal Officer
1,750
0.0034%
$23.71$41,494-38.09%
2024-05-16SaleChief Legal Officer
1,750
0.0034%
$25.45$44,541-40.52%
2024-04-16SaleChief Legal Officer
1,750
0.0034%
$25.74$45,045-39.63%
2024-04-01SaleChief Legal Officer
8,153
0.0173%
$31.78$259,102-42.84%
2024-03-27SaleChief Legal Officer
5,833
0.0114%
$35.04$204,410-50.67%
2024-03-18SaleChief Legal Officer
1,750
0.0035%
$31.27$54,723-32.29%
2024-02-27SaleChief Legal Officer
1,909
0.0039%
$30.00$57,270-23.30%
2024-02-16SaleChief Legal Officer
1,750
0.0036%
$27.67$48,423-14.56%
2024-02-08SaleChief Executive Officer
92,001
0.3275%
$27.13$2.5M-11.52%
2024-02-08SaleChief Legal Officer
1,996
0.0072%
$27.50$54,890-11.52%
2024-02-05SaleChief Medical Officer
6,552
0.0258%
$30.05$196,888-25.83%
2024-01-23SaleChief Executive Officer
5,696
0.0133%
$18.41$104,851+27.40%
2024-01-05SaleChief Executive Officer
28,237
0.0659%
$19.57$552,478+15.78%

Insider Historical Profitability

<0.0001%
VIKING GLOBAL INVESTORS LP10 percent owner
4247914
9.1891%
$8.0221<0.0001%
YAO TONY DUNG LINGdirector
1060880
2.2949%
$8.0210<0.0001%
MILLIGAN JOHN Fdirector
100000
0.2163%
$8.0210<0.0001%
Kamal FariborzSee Remarks
4347
0.0094%
$8.0210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$160.94M9.775.05M+21.34%+$28.3M0.16
Vr Adviser Llc$140.18M8.514.4M+28.5%+$31.09M6.81
BlackRock$136.51M8.294.28M+23.67%+$26.12M<0.01
Bvf Inc Il$124.97M7.593.92M-2.12%-$2.71M0.92
Janus Henderson$101.84M6.183.2M+3.37%+$3.32M0.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.